On Apr. 16, 2020, Dynavax and Sinovac Biotech, a leading provider of biopharmaceutical products in China, announced a collaboration to develop a vaccine to prevent COVID-19. The collaboration will evaluate the combination of Sinovacﾒs chemically inactivated coronavirus vaccine candidate, with Dynavaxﾒs advanced adjuvant, CpG 1018 ﾙ.

CpG 1018 is the adjuvant used in HEPLISAV-Bﾮ [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the FDA.